SYGNIS AG acquires profitable life sciences tools company C.B.S. Scientific for US $0.9 million in cash and shares

SYGNIS AG / Key word(s): Takeover

21-Dec-2016 / 11:59 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc announcement according to § 17 MAR

---------------------------------------------------------------------------

NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN USA, CANADA, JAPAN
AND AUSTRALIA

SYGNIS AG acquires profitable life sciences tools company C.B.S. Scientific
for US $0.9 million in cash and shares


- C.B.S. estimated revenues in excess of $1,500,000 in 2016

- Profitable and cash generative

- Strong sales synergies and significant potential for future revenue
growth

Madrid, Spain, and Heidelberg, Germany, 21 December, 2016 - SYGNIS AG
(Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced the
execution of a binding agreement for the acquisition of C.B.S. Scientific
Company Inc. (C.B.S.), a profitable Life Sciences tools company located in
San Diego, USA.

SYGNIS will pay a total consideration of $900,000 of which $540,000 is in
cash, funded from existing cash balances and $360,000 in the form of
275,311 new shares in SYGNIS AG to be issued from authorized capital. Five-
sixths (5/6) of the shares issued to C.B.S stock holders will be restricted
from trading for six months from the date of the registration of the
excecution of the respective capital increase. After this period of time,
with the beginning of every month, one-sixth (1/6) of the new shares shall
be released from the aforementioned lock-up rule.

The acquisition of C.B.S is anticipated to be earnings enhancing and cash
generative from the onset. Current revenues are in excess of $1,500,000
p.a. and the strong synergies between the C.B.S and SYGNIS product
portfolios, plus the sales and customer base provide a clear opportunity
for solid post acquisition revenue growth. Combining the Expedeon business
location in San Diego and C.B.S will allow additional cost savings.

**** End of ad hoc announcement ****

For further information, please contact:


SYGNIS AG
Dr. Heikki Lanckriet
Co-CEO/CSO
Phone : +44 1223 873 364
Email: heikki.lanckriet@sygnis.com

Pilar de la Huerta
Co-CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com


MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: raimund.gabriel@mc-services.eu


About SYGNIS AG: www.sygnis.com

SYGNIS AG is specialized in the development and the commercialization of
proprietary technologies and offers a wide range of different commercial
products addressing key challenges in molecular biology. With the
acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has
added a complementary proteomic product portfolio. Resulting from this
significant expansion, SYGNIS' product portfolio now covers the entire
workflow of molecular biology. The products are sold through a direct sales
force and several distribution partners in Europe, the US and Asia. SYGNIS
AG has offices in Germany, Spain and the UK, production sites in the UK and
the US as well as sales offices in Asia. The company is listed on the
German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker:
LIO1; ISIN: DE000A1RFM03).

### The information contained herein does not constitute an offer to sell
or a solicitation of an offer to purchase any securities of SYGNIS AG in
the Federal Republic of Germany nor under any other jurisdiction, in
particular not where such kind of offer or solicitation is prohibited or
lacks the required permission. Potential investors in securities of SYGNIS
AG are asked to familiarize themselves with and to observe the respective
restrictions.

The information in this document may not be disseminated outside the
Federal Republic of Germany in particular not in the United States, to U.S.
Persons (as defined in regulation S of the U.S. Securities Act of 1933) or
to publications with a general circulation in the United States with the
exception of a such disclosures or announcements outside the Federal
Republic of Germany which have to be made under the respective mandatory
law. Any person who fails to comply with these restrictions may violate the
security laws of certain jurisdictions, in particular of the United States.
Securities in SYGNIS AG are not publicly offered outside the Federal
Republic of Germany.

Some statements included in this ad hoc announcement, relating neither to
proven financial results nor other historical data, should be viewed as
forward-looking, i.e. not definite. Such statements are mainly predictions
of future results, trends, plans or goals. These statements should not be
considered to be total guarantees since given their very nature they are
subject to known and unknown risks and imponderability and can be affected
by other factors as a consequence of which the actual results, plans and
goals of SYGNIS AG may deviate greatly from the established conclusions or
implied predictions contained in such statements. SYGNIS does not undertake
to publicly update or revise these statements in the light of new
information or future results or for any other reason.###

---------------------------------------------------------------------------

21-Dec-2016 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: SYGNIS AG
Waldhofer Str. 104
69123 Heidelberg
Germany
Phone: +49 (0) 6221 3540 125
Fax: +49 (0) 6221 3540 127
E-mail: investors@sygnis.com
Internet: www.sygnis.com
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange



End of Announcement DGAP News Service